Down-regulation of A20 mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus

Journal of Clinical Immunology

Volumn 32, Issue 6, 2012, Pages 1287-1291

  Li, Di ^a,c   Wang, Lei ^a   Fan, Yuchen ^b   Song, Lijun ^b   Guo, Chun ^a   Zhu, Faliang ^a   Zhang, Lining ^a   Shi, Yongyu ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c QINGDAO MUNICIPAL HOSPITAL   (China)

Author keywords

A20; real time reverse transcription polymerase chain reaction analysis; SLEDAI; systemic lupus erythematosus; tumor necrosis factor induced protein 3

Indexed keywords

MESSENGER RNA; DNA BINDING PROTEIN; NUCLEAR PROTEIN; SIGNAL PEPTIDE; TNFAIP3 PROTEIN, HUMAN;

A20 GENE; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MOLECULAR PATHOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REGULATOR GENE; SYSTEMIC LUPUS ERYTHEMATOSUS; ADOLESCENT; BLOOD; CASE CONTROL STUDY; GENE EXPRESSION; GENETICS; METABOLISM; MONONUCLEAR CELL; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; DNA-BINDING PROTEINS; DOWN-REGULATION; FEMALE; GENE EXPRESSION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; NUCLEAR PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION;

EID: 84878259901     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-012-9764-2     Document Type: Article

References (24)

1. Apostolidis SA, Lieberman LA, Kis-Toth K, et al. The dysregulation of cytokine networks in systemic lupus erythematosus. J Interferon Cytokine Res. 2011;31:769-79.
2. Hrycek A, Kusmierz D, Dybała T, et al. Expression of messenger RNA for transforming growth factor-beta1 and for transforming growth factor-beta receptors in peripheral blood of systemic lupus erythematosus patients treated with low doses of quinagolide. Autoimmunity. 2007;40:23-30.
3. Wong CK, Lit LC, Tam LS, et al. Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005;44:989-94.
4. Fujimoto M, Tsutsui H, Xinshou O, et al. Inadequate induction of suppressor of cytokine signaling-1 causes systemic autoimmune diseases. Int Immunol. 2004;16:303-14.
5. Zhang B, Zhang X, Tang F, et al. Reduction of forkhead box P3 levels in CD4 + CD25high T cells in patients with new-onset systemic lupus erythematosus. Clin Exp Immunol. 2008;153:182-7.
6. Vereecke L, Beyaert R, van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 2009;30:383-91.
7. Coornaert B, Carpentier I, Beyaert R. A20: central gatekeeper in inflammation and immunity. J Biol Chem. 2009;284:8217-21.
8. Kingeter LM, Paul S, Maynard SK, et al. Cutting edge: TCR ligation triggers digital activation of NF-kappaB. J Immunol. 2010;185:4520-4.
9. Düwel M, Welteke V, Oeckinghaus A, et al. A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains. J Immunol. 2009;182:7718-28.
10. Verstrepen L, Verhelst K, van Loo G, et al. Expression, biological activities and mechanisms of action of A20 (TNFAIP3). Biochem Pharmacol. 2010;80:2009-20.
11. Vereecke L, Beyaert R, van Loo G. Genetic relationships between A20/TNFAIP3, chronic inflammation and autoimmune disease. Biochem Soc Trans. 2011;39:1086-91.
12. Hövelmeyer N, Reissig S, Xuan NT, et al. A20 deficiency in B cells enhances B-cell proliferation and results in the development of autoantibodies. Eur J Immunol. 2011;41:595-601.
13. Ohl K, Tenbrock K. Inflammatory cytokines in systemic lupus erythematosus. J Biomed Biotechnol. 2011;2011:432595.
14. Matmati M, Jacques P, Maelfait J, et al. A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet. 2011;43:908-12.
15. Bombardier C, Gladman DD, Hurwitz MB, et al. Derivation of the SLEDAI: a disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum. 1992;35:630-40.
16. Hawker G, Gabriel S, Bombardier C, et al. A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus. J Rheumatol. 1993;20:657-60.
17. Boonyasrisawat W, Eberle D, Bacci S, et al. Tag polymorphisms at the A20 (TNFAIP3) locus are associated with lower gene expression and increased risk of coronary artery disease in type 2 diabetes. Diabetes. 2007;56:499-505.
18. Adrianto I, Wen F, Templeton A, et al. Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet. 2011;43:253-8.
19. Frenzel LP, Claus R, Plume N, et al. Sustained NF-kappaB activity in chronic lymphocytic leukemia is independent of genetic and epigenetic alterations in the TNFAIP3 (A20) locus. Int J Cancer. 2011;128:2495-500.
20. Chanudet E, Huang Y, Ichimura K, et al. A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma. Leukemia. 2010;24:483-7.
21. Graham RR, Cotsapas C, Davies L, et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet. 2008;40:1059-61.
22. Musone SL, Taylor KE, Lu TT, et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet. 2008;40:1062-4.
23. Tavares RM, Turer EE, Liu CL, et al. The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity. 2010;33:181-91.
24. Kool M, van Loo G, Waelput W, et al. The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity. Immunity. 2011;35:82-96.